Market Overview

Needham Says Buy the Dip in Isis Pharma, Didn't See Favorable Chance CRP Would Be Indicated for RA

Related ISIS
Biotech Stocks Sell Off, ETFs Fall Over 5%
Worst Performing Industries For December 23, 2014
Making Money With Charles Payne: 10/08/14 (Fox Business)

Shares of Isis Pharma (NASDAQ: ISIS) have fallen nearly 3 percent Monday as the company announced it has halted development of its rheumatoid arthritis product as the latest study failed to demonstrate a benefit.

Needham analyst Chad Messer issued a research note earlier suggesting investors should use the dip in price to load up on shares. Messer pointed out he didn't consider the RA drug as a "serious consideration" for the company's ISIS-CRP. He believes the next catalyst for APOCIII monotherapy trial is later in August.

Needham maintains a Buy rating and $36 price target on shares of Isis Pharma.

Latest Ratings for ISIS

DateFirmActionFromTo
Dec 2014JP MorganMaintainsNeutral
Dec 2014Stifel NicolausMaintainsBuy
Sep 2014Leerink SwannAssumesMarket Perform

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (ISIS)

Around the Web, We're Loving...

Get Benzinga's Newsletters